CoChat

Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus

Open access
Dematteis, Maurice, Auriacombe, Marc, D’Agnone, Oscar, Somaini, Lorenzo, Szerman, Néstor, Littlewood, Richard, Alam, Farrukh, Alho, Hannu, Benyamina, Amine, Bobes, Julio, Daulouede, Jean Pierre, Leonardi, Claudio, Maremmani, Icro, Torrens, Marta, Walcher, Stephan, Soyka, Michael · 2017 · Expert Opinion on Pharmacotherapy

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society. Areas covered: The use of methadone and buprenorphine within an integrated treatment plan in the management of patients with OUD: this work provides consensus recommendation on pharmacotherapy in OUD to assist clinicians with practical decision making in this field. Expert opinion: Pharmacotherapy is recommended as part of an integrated OUD treatment approach with psychosocial interventions, with the goal of reducing risks of illicit opioid use, overdose mortality, infection with HIV or HCV, improving health, psychological and social outcomes. Access to OAT should be prioritised in the treatment of OUD. Treatment choices in OUD pharmacotherapy should be based on the needs of the individual and characteristics of medications. Recommendations for choices of OAT are based on clinical efficacy, safety, patient preference, side effects, pharmacological interactions, quality of life, dose titration potential and outcomes (control craving, ongoing opioids consumption or other drugs, and potentially psychiatric comorbidities). Special groups, pregnant women, prisoners, patients with mental health problems have specific needs which must be addressed with expert input.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2017.1409722

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 79 references

Research works printed but not linked: 28

  1. Auriacombe M, 2017, The Routle, 500
  2. College of Physicians and Surgeons of British Columbia, 2016, Methadone and buprenorphine: clinical practice guideline for opioid use disorder
  3. College of Physicians and Surgeons of Saskatchewan, 2015, Saskatchewan methadone guidelines and standards for the treatment of opioid addiction/dependence
  4. Advisory Council on the Misuse of Drugs (ACMD), 2015, How can opioid substitution therapy (and drug treatment and recovery systems) be optimised to maximise recovery outcomes for service users?
  5. Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group, 2017, Drug misuse and dependence. Drug misuse and dependence: UK guidelines on clinical management
  6. Ministry of Health, 2014, New Zealand practice guidelines for opioid substitution treatment
  7. SAMHSA. Chapter 2. History of medication-assisted treatment for opioid addiction. In: medication-assisted treatment for opioid addiction in opioid treatment programs [Internet]. Rockville; 2005. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64157/
  8. Gowing L, 2014, National guidelines for medication-assisted treatment of opioid dependence
  9. Departement for the Treatment of Substance Abuse, 2017, Policy of the department for the treatment of substance abuse: treatment of opioid addiction through psychosocial therapy and maintenance treatment (agonists and partial agonists such as: methadone, buprenorphine/buprenorphine/naloxone)
  10. The Swedish National Board of Health and Welfare (Support for governance and management), 2016, National guidelines for care and support in cases of misuse and addiction
  11. College of Psychiatrists in Ireland, 2016, Heal Serv Exec [Internet]
  12. Meesmann U, 2011, Main DRUID results to be communicated to different target groups
  13. Maremmani I, 1999, Heroin Addict Relat Clin Probl, 1, 7
  14. Leavitt SB, 2000, Mt Sinai J Med [Internet], 67, 404
  15. Walton G, 2015, BMJ Case Rep [Internet], 2015210239
  16. Soyka M, 2014, Adv Pharmacoepidemiol Drug Saf [Internet], 3
  17. Hser Y-I, 2014, Natl Inst Heal, 109, 79
  18. Mattick RP, 2014, Cochrane Database Syst Rev [Internet], 2, CD002207
  19. Curcio F, 2011, Eur Rev Med Pharmacol Sci, 15, 871
  20. Parvaresh N, 2012, Addict Heal, 4, 1
  21. Maremmani AGI, 2011, Ann Gen Psychiatry [Internet], 10
  22. FDA, 2017, Opioid addiction medications in patients taking benzodiazepines or CNS Depressants : drug safety communication - careful medication management can reduce risks
  23. Javaher S, 2015, J Pain, 1
  24. Auriacombe M, 2016, Traité d’addictologie, 307
  25. Substance abuse and mental health services administration. Medication-assisted treatment for opioid addiction in opioid treatment programs [Internet]. 2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64164/%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/22514849
  26. National collaborating centre for mental health (UK). Drug misuse: opioid detoxification [Internet]. British Psychological Society. British Psychological Society; 2008. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21452460
  27. Fischer G, 2012, Heroin Addict Relat Clin Probl, 14, 39
  28. Saulle R, 2017, Cochrane Database Syst Rev, 2017, 4

Cited by

See all 147

Metadata

Authors
Dematteis, M., Auriacombe, M., D’Agnone, O., Somaini, L., Szerman, N., Littlewood, R., Alam, F., Alho, H., Benyamina, A., Bobes, J., Daulouede, J. P., Leonardi, C., Maremmani, I., Torrens, M., Walcher, S., & Soyka, M.
Affiliations
  • Department of Addiction Medicine, Grenoble Alpes University Hospital, Grenoble, France
  • Centre National de la Recherche Scientifique (FR)
  • University of Manchester (GB)
  • Addiction Treatment Centre, Biella, Italy
  • Hospital General Universitario Gregorio Marañón (ES)
  • Applied strategic, London, UK
  • Central and North West London NHS Foundation Trust (GB)
  • University of Helsinki (FI)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Universidad de Oviedo (ES)
  • Université de Bordeaux, Bordeaux, France
  • ASL Roma (IT)
  • University of Pisa (IT)
  • Universitat Autònoma de Barcelona (ES)
  • CONCEPT, Addiction Medicine, Munich, Germany
  • Ludwig-Maximilians-Universität München (DE)
Venue
Expert Opinion on Pharmacotherapy
Published
2017-12-03
Volume
18
Issue
18
Pages
1987-1999
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2769074706
Cited by
141
References
80
Citations by year
2026: 7 · 2025: 18 · 2024: 12 · 2023: 13 · 2022: 23 · 2021: 17 · 2020: 20 · 2019: 16 · 2018: 15
FWCI
13.10
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
  • Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
Funders
Indivior (Expert meeting attendance, no influence on content)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
opioid use disorder, buprenorphine, methadone, opioid substitution therapy, pharmacotherapy, integrated treatment, psychosocial interventions, drug overdose deaths, craving, dose titration, pregnant women, prisoners, psychiatric comorbidity, treatment guidelines
MeSH terms
Mental Disorders, Buprenorphine, Europe, Humans, Methadone, Opioid-Related Disorders, Quality of Life, Consensus, Risk Reduction Behavior, Patient Preference, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. https://app.cochat.ai/papers/10.1080/14656566.2017.1409722
The paper
Dematteis, M., Auriacombe, M., D’Agnone, O., Somaini, L., Szerman, N., Littlewood, R., Alam, F., Alho, H., Benyamina, A., Bobes, J., Daulouede, J. P., Leonardi, C., Maremmani, I., Torrens, M., Walcher, S., & Soyka, M. (2017). Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2017.1409722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.